NO311692B1 - Sukkersubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler - Google Patents

Sukkersubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler Download PDF

Info

Publication number: NO311692B1
Authority: NO; Norway
Prior art keywords: phenyl; fluorophenyl; trans; oxo; azetidinyl
Prior art date: 1995-10-31

Application number

NO19981950A

Other languages

English (en)

Norwegian (no)

Other versions

NO981950L (no

NO981950D0 (no

Inventor

Nathan P Yumibe

Kevin B Alton

Margaret Van Heek

Harry R Davis

Wayne D Vaccaro

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-31

Filing date

1998-04-29

Publication date

2002-01-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26677904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO311692(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-29 Application filed by Schering Corp filed Critical Schering Corp

1998-04-29 Publication of NO981950D0 publication Critical patent/NO981950D0/no

1998-06-26 Publication of NO981950L publication Critical patent/NO981950L/no

2002-01-07 Publication of NO311692B1 publication Critical patent/NO311692B1/no

Links

MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title description 33
239000003529 anticholesteremic agent Substances 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims description 93
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 81
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
235000012000 cholesterol Nutrition 0.000 claims description 29
238000000034 method Methods 0.000 claims description 24
230000015572 biosynthetic process Effects 0.000 claims description 23
239000003112 inhibitor Substances 0.000 claims description 20
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
125000001424 substituent group Chemical group 0.000 claims description 12
229960002246 beta-d-glucopyranose Drugs 0.000 claims description 10
206010003210 Arteriosclerosis Diseases 0.000 claims description 9
208000011775 arteriosclerosis disease Diseases 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
230000009467 reduction Effects 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical group FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
235000019439 ethyl acetate Nutrition 0.000 description 40
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
239000000203 mixture Substances 0.000 description 36
239000000047 product Substances 0.000 description 26
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
239000000243 solution Substances 0.000 description 25
239000000843 powder Substances 0.000 description 23
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
235000000346 sugar Nutrition 0.000 description 19
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
210000004185 liver Anatomy 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
239000012267 brine Substances 0.000 description 11
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
239000011734 sodium Substances 0.000 description 11
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
239000007787 solid Substances 0.000 description 11
239000007858 starting material Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
125000002947 alkylene group Chemical group 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 10
125000006239 protecting group Chemical group 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
150000001840 cholesterol esters Chemical class 0.000 description 8
-1 Glycoside derivatives of tigogenin Chemical class 0.000 description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000011521 glass Substances 0.000 description 6
239000002245 particle Substances 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000006260 foam Substances 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
LHPLPOXXRVHYBK-DNQXCXABSA-N (3r,4s)-4-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)[C@H](CCCC=2C=CC=CC=2)[C@H]1C1=CC=C(O)C=C1 LHPLPOXXRVHYBK-DNQXCXABSA-N 0.000 description 4
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000012458 free base Substances 0.000 description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
239000012442 inert solvent Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
235000012239 silicon dioxide Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
101150041968 CDC13 gene Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
108090001030 Lipoproteins Proteins 0.000 description 3
102000004895 Lipoproteins Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108010062497 VLDL Lipoproteins Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229910052681 coesite Inorganic materials 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
229910052906 cristobalite Inorganic materials 0.000 description 3
239000013078 crystal Substances 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
239000012065 filter cake Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
CLHFNXQWJBTGBL-HTGOSZRMSA-N methyl (2s,3s,4s,5r)-3,4,5-triacetyloxy-6-hydroxyoxane-2-carboxylate Chemical compound COC(=O)[C@H]1OC(O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O CLHFNXQWJBTGBL-HTGOSZRMSA-N 0.000 description 3
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229910052682 stishovite Inorganic materials 0.000 description 3
229910052905 tridymite Inorganic materials 0.000 description 3
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
229910004373 HOAc Inorganic materials 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
239000007832 Na2SO4 Substances 0.000 description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
229910004298 SiO 2 Inorganic materials 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 2
DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000004450 alkenylene group Chemical group 0.000 description 2
239000002585 base Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000001906 cholesterol absorption Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
125000002993 cycloalkylene group Chemical group 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 2
WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229960003765 fluvastatin Drugs 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000000871 hypocholesterolemic effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
230000033227 intestinal cholesterol absorption Effects 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
229960002965 pravastatin Drugs 0.000 description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
229960002855 simvastatin Drugs 0.000 description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
229940031439 squalene Drugs 0.000 description 2
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
OGOMAWHSXRDAKZ-RUOAZZEASA-N (2s,3r,4s,5r,6r)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-ol Chemical compound C([C@H]1O[C@@H]([C@@H]([C@@H](OCC=2C=CC=CC=2)[C@@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)O)OCC1=CC=CC=C1 OGOMAWHSXRDAKZ-RUOAZZEASA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
GJUUWOLMGNFCGN-FQLXRVMXSA-N (3r,4s)-1-(4-benzoylphenyl)-4-(4-hydroxyphenyl)-3-(3-phenylpropyl)azetidin-2-one Chemical compound C1=CC(O)=CC=C1[C@H]1N(C=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 GJUUWOLMGNFCGN-FQLXRVMXSA-N 0.000 description 1
ZYMCBJWUWHHVRX-UHFFFAOYSA-N (4-nitrophenyl)-phenylmethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC=CC=C1 ZYMCBJWUWHHVRX-UHFFFAOYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
ZVTWZSXLLMNMQC-UHFFFAOYSA-N 4-phenylmethoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCC1=CC=CC=C1 ZVTWZSXLLMNMQC-UHFFFAOYSA-N 0.000 description 1
VSHULXBTMXBAAP-UHFFFAOYSA-N 5-phenylpentanoyl chloride Chemical compound ClC(=O)CCCCC1=CC=CC=C1 VSHULXBTMXBAAP-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 1
RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000006270 aryl alkenylene group Chemical group 0.000 description 1
150000001499 aryl bromides Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
JGZVCCVFRMQHQJ-NVUQYOTJSA-N benzyl (2s,3s,4s,5r)-6-hydroxy-3,4,5-tris(phenylmethoxy)oxane-2-carboxylate Chemical compound O([C@@H]1[C@H](OC([C@@H]([C@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)O)C(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 JGZVCCVFRMQHQJ-NVUQYOTJSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
229920000080 bile acid sequestrant Polymers 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000031154 cholesterol homeostasis Effects 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002849 elastaseinhibitory effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
AYEIJQRLYWJQHC-UHFFFAOYSA-N methylsulfanylmethane;trichloroborane Chemical compound CSC.ClB(Cl)Cl AYEIJQRLYWJQHC-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
150000003378 silver Chemical class 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
REDSKZBUUUQMSK-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC.CCCC[Sn](CCCC)CCCC REDSKZBUUUQMSK-UHFFFAOYSA-N 0.000 description 1
230000007306 turnover Effects 0.000 description 1
DFKDOZMCHOGOBR-NCSQYGPNSA-N zaragozic acid A Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CC[C@]12[C@H](O)[C@H]([C@](O2)(C(O)=O)[C@@](O)([C@H](O1)C(O)=O)C(O)=O)OC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)C1=CC=CC=C1 DFKDOZMCHOGOBR-NCSQYGPNSA-N 0.000 description 1
DFKDOZMCHOGOBR-UHFFFAOYSA-N zaragozic acid A Natural products O1C(C(O)(C(O2)C(O)=O)C(O)=O)(C(O)=O)C(OC(=O)C=CC(C)CC(C)CC)C(O)C21CCC(=C)C(OC(C)=O)C(C)CC1=CC=CC=C1 DFKDOZMCHOGOBR-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19981950A 1995-10-31 1998-04-29 Sukkersubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler NO311692B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US818595P	1995-10-31	1995-10-31
US57084795A	1995-12-12	1995-12-12
PCT/US1996/016823 WO1997016455A1 (en)	1995-10-31	1996-10-29	Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents

Publications (3)

Publication Number	Publication Date
NO981950D0 NO981950D0 (no)	1998-04-29
NO981950L NO981950L (no)	1998-06-26
NO311692B1 true NO311692B1 (no)	2002-01-07

Family

ID=26677904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19981950A NO311692B1 (no)	1995-10-31	1998-04-29	Sukkersubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler

Country Status (27)

Country	Link
EP (1)	EP0877750B1 (es)
JP (2)	JP3385031B2 (es)
KR (1)	KR100311554B1 (es)
CN (1)	CN1103780C (es)
AR (1)	AR004701A1 (es)
AT (1)	ATE219495T1 (es)
AU (1)	AU712158B2 (es)
BR (2)	BR9611401B1 (es)
CA (1)	CA2235943C (es)
CY (1)	CY2353B1 (es)
CZ (1)	CZ293957B6 (es)
DE (1)	DE69621952T2 (es)
DK (1)	DK0877750T3 (es)
ES (1)	ES2175141T3 (es)
GE (1)	GEP20033006B (es)
HU (1)	HU226822B1 (es)
ID (1)	ID16177A (es)
IL (1)	IL124268A (es)
MX (1)	MX9803447A (es)
MY (1)	MY114803A (es)
NO (1)	NO311692B1 (es)
NZ (1)	NZ321766A (es)
PL (1)	PL184698B1 (es)
PT (1)	PT877750E (es)
SK (1)	SK283552B6 (es)
TW (1)	TW448181B (es)
WO (1)	WO1997016455A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5633246A (en) *	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE10042447A1 (de) *	2000-08-29	2002-03-28	Aventis Pharma Gmbh	Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
SK286703B6 (sk) *	2000-12-20	2009-03-05	Schering Corporation	Cukrom-substituované 2-azetidinóny, farmaceutický prostriedok s ich obsahom a ich použitie
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) *	2000-12-20	2005-03-02	Schering Corporation	Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
DE10064398A1 (de) *	2000-12-21	2002-06-27	Aventis Pharma Gmbh	Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE50111751D1 (de)	2000-12-21	2007-02-08	Sanofi Aventis Deutschland	Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1355644T1 (sl) *	2001-01-26	2006-10-31	Schering Corp	Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
KR20040025890A (ko) *	2001-01-26	2004-03-26	쉐링 코포레이션	혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
AU2005246926B2 (en) *	2001-01-26	2008-02-28	Merck Sharp & Dohme Corp.	The use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TWI291957B (en) *	2001-02-23	2008-01-01	Kotobuki Pharmaceutical Co Ltd	Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
RS50386B (sr)	2001-03-28	2009-12-31	Schering Corporation,	Enantioselektivna sinteza intermedijarnih jedinjenja azetidinona
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DK1429756T3 (da)	2001-09-21	2007-03-19	Schering Corp	Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7671047B2 (en)	2002-06-19	2010-03-02	Sanofi-Aventis Deutschland Gmbh	Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) *	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en)	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en)	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040092499A1 (en)	2002-11-06	2004-05-13	Schering Corporation	Methods and therapeutic combinations for the treatment of autoimmune disorders
ATE418551T1 (de)	2003-03-07	2009-01-15	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2005015434A (ja)	2003-06-27	2005-01-20	Kotobuki Seiyaku Kk	血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (en)	2003-10-07	2005-04-13	Lipideon Biotechnology AG	Novel hypocholesterolemic compounds
CN1870988A (zh) *	2003-10-30	2006-11-29	默克公司	作为抗高胆固醇血症药的2－氮杂环丁烷酮
WO2005061452A1 (en)	2003-12-23	2005-07-07	Astrazeneca Ab	Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US20060211752A1 (en)	2004-03-16	2006-09-21	Kohn Leonard D	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
JP2008539255A (ja) *	2005-04-26	2008-11-13	マイクロビアインコーポレーテッド	高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AR060623A1 (es)	2006-04-27	2008-07-02	Astrazeneca Ab	Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20080319221A1 (en)	2007-06-22	2008-12-25	Bernd Junker	Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007063671A1 (de)	2007-11-13	2009-06-25	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2754384A1 (en)	2009-03-06	2010-09-10	Lipideon Biotechnology Ag	Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh)	2009-08-11	2012-07-11	浙江海正药业股份有限公司	氮杂环丁酮类化合物及医药应用
CN103102297A (zh) *	2012-09-28	2013-05-15	北京赛林泰医药技术有限公司	一种新的依折麦布的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3595B (en)	1993-01-21	1995-12-27	Schering Corp	Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2120221A1 (en) *	1993-04-23	1994-10-24	Allan W. Rey	N-substituted 2-azetidinones
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en)	1994-03-25	1997-05-06	Schering Corporation	Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en)	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

1996
- 1996-10-29 AT AT96937702T patent/ATE219495T1/de active
- 1996-10-29 CA CA002235943A patent/CA2235943C/en not_active Expired - Lifetime
- 1996-10-29 CN CN96199226A patent/CN1103780C/zh not_active Expired - Lifetime
- 1996-10-29 EP EP96937702A patent/EP0877750B1/en not_active Expired - Lifetime
- 1996-10-29 NZ NZ321766A patent/NZ321766A/xx not_active IP Right Cessation
- 1996-10-29 IL IL12426896A patent/IL124268A/xx not_active IP Right Cessation
- 1996-10-29 SK SK483-98A patent/SK283552B6/sk not_active IP Right Cessation
- 1996-10-29 KR KR1019980703155A patent/KR100311554B1/ko not_active Expired - Fee Related
- 1996-10-29 DK DK96937702T patent/DK0877750T3/da active
- 1996-10-29 BR BRPI9611401-0A patent/BR9611401B1/pt not_active IP Right Cessation
- 1996-10-29 ES ES96937702T patent/ES2175141T3/es not_active Expired - Lifetime
- 1996-10-29 JP JP51738697A patent/JP3385031B2/ja not_active Expired - Fee Related
- 1996-10-29 HU HU9802539A patent/HU226822B1/hu unknown
- 1996-10-29 AR ARP960104954A patent/AR004701A1/es not_active Application Discontinuation
- 1996-10-29 GE GEAP19966589A patent/GEP20033006B/en unknown
- 1996-10-29 WO PCT/US1996/016823 patent/WO1997016455A1/en not_active Ceased
- 1996-10-29 MY MYPI96004488A patent/MY114803A/en unknown
- 1996-10-29 PT PT96937702T patent/PT877750E/pt unknown
- 1996-10-29 DE DE69621952T patent/DE69621952T2/de not_active Expired - Lifetime
- 1996-10-29 AU AU75179/96A patent/AU712158B2/en not_active Ceased
- 1996-10-29 CZ CZ19981294A patent/CZ293957B6/cs not_active IP Right Cessation
- 1996-10-29 TW TW085113142A patent/TW448181B/zh not_active IP Right Cessation
- 1996-10-29 PL PL96327987A patent/PL184698B1/pl not_active IP Right Cessation
- 1996-10-29 BR BRPI9612998-0A patent/BR9612998B1/pt not_active IP Right Cessation
- 1996-10-30 ID IDP963136A patent/ID16177A/id unknown
1998
- 1998-04-29 NO NO19981950A patent/NO311692B1/no not_active IP Right Cessation
- 1998-04-30 MX MX9803447A patent/MX9803447A/es unknown
2000
- 2000-07-17 JP JP2000216704A patent/JP2001048895A/ja not_active Withdrawn
2003
- 2003-01-29 CY CY0300007A patent/CY2353B1/xx unknown

Also Published As

Publication number	Publication date
EP0877750B1 (en)	2002-06-19
HUP9802539A3 (en)	1999-12-28
CN1205707A (zh)	1999-01-20
JPH10512592A (ja)	1998-12-02
ID16177A (id)	1997-09-11
JP3385031B2 (ja)	2003-03-10
DK0877750T3 (da)	2002-07-15
CY2353B1 (en)	2004-06-04
ATE219495T1 (de)	2002-07-15
DE69621952D1 (de)	2002-07-25
AR004701A1 (es)	1999-03-10
GEP20033006B (en)	2003-07-10
CN1103780C (zh)	2003-03-26
HK1012507A1 (en)	1999-08-06
AU712158B2 (en)	1999-10-28
CZ293957B6 (cs)	2004-08-18
IL124268A (en)	2005-08-31
ES2175141T3 (es)	2002-11-16
CA2235943A1 (en)	1997-05-09
MY114803A (en)	2003-01-31
JP2001048895A (ja)	2001-02-20
SK283552B6 (sk)	2003-09-11
SK48398A3 (en)	1998-11-04
AU7517996A (en)	1997-05-22
NO981950L (no)	1998-06-26
BR9611401A (pt)	1999-01-05
KR19990067202A (ko)	1999-08-16
PL327987A1 (en)	1999-01-04
BR9612998B1 (pt)	2010-03-23
HUP9802539A2 (hu)	1998-11-30
PT877750E (pt)	2002-09-30
NO981950D0 (no)	1998-04-29
WO1997016455A1 (en)	1997-05-09
CA2235943C (en)	2002-10-01
CZ129498A3 (cs)	1998-10-14
TW448181B (en)	2001-08-01
PL184698B1 (pl)	2002-12-31
DE69621952T2 (de)	2003-01-16
EP0877750A1 (en)	1998-11-18
MX9803447A (es)	1998-09-30
BR9611401B1 (pt)	2010-08-10
HU226822B1 (en)	2009-11-30
NZ321766A (en)	1999-07-29
KR100311554B1 (ko)	2002-06-20

Publication	Publication Date	Title
NO311692B1 (no)	2002-01-07	Sukkersubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler
US5756470A (en)	1998-05-26	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5656624A (en)	1997-08-12	4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EP0681569B1 (en)	2001-03-21	Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US6982251B2 (en)	2006-01-03	Substituted 2-azetidinones useful as hypocholesterolemic agents
US5698527A (en)	1997-12-16	Steroidal glycosides as antihyperlipidemic agents
AU2004308332B2 (en)	2008-04-10	Anti-hypercholesterolemic compounds
FI110321B (fi)	2002-12-31	Menetelmä valmistaa hydroksisubstituoituja atsetidinoniyhdisteitä, jotka ovat käyttökelpoisia hypokolesterolemisia yhdisteitä
JP4351842B2 (ja)	2009-10-28	低コレステロール血症剤として有用な糖置換２−アゼチジノン
US4634765A (en)	1987-01-06	Homodisaccharide hypoglycemic agents
BG61118B2 (bg)	1996-11-29	Заместени бета-лактамни съединения,приложими като хипохолестеролемични агенти и метод за получаването им
JP4879991B2 (ja)	2012-02-22	抗高コレステロール血症化合物
EP0310519A1 (fr)	1989-04-05	Nouveaux esters d'acide androstane 17-carboxylique, procédé pour leur préparation et médicament les contenant
DE3106815A1 (de)	1982-09-09	"chemische verbindungen, verfahren zu ihrer herstellung und ihre verwendung als antigene oder immunadsorbentien"
HK1012507B (en)	2002-10-18	Sugar-substituted, 2-azetidinones useful as hypocholesterolemic a gents
US4003998A (en)	1977-01-18	α-Acyl derivatives of digitoxin
SI9200316A (sl)	1994-09-30	Substituirane beta-laktamske spojine uporabne kot hipoholesterolemiki in postopki njih priprave

Legal Events

Date	Code	Title	Description
2012-09-24	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US
2015-05-26	MM1K	Lapsed by not paying the annual fees

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2015-05-26

MM1K

Lapsed by not paying the annual fees